Filgrastim biosimilar - Reliance Life Sciences
Alternative Names: Recombinant G-CSF - Reliance Life Sciences; ReliGrastLatest Information Update: 12 Nov 2021
At a glance
- Originator Reliance Life Sciences
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor replacements; Granulocyte colony-stimulating factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Neutropenia
Most Recent Events
- 28 Sep 2021 Discontinued - Phase-III for Neutropenia in Europe (Parenteral)
- 30 Jul 2009 Phase-III clinical trials in Neutropenia in Europe (Parenteral)
- 30 Jul 2008 Launched for Neutropenia in India (Parenteral)